228. Bronchiolitis obliterans Clinical trials / Disease details
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03315741 (ClinicalTrials.gov) | March 1, 2018 | 5/10/2017 | The Safety and Tolerability of Pirfenidone for BOS After HCT | The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation | Bronchiolitis Obliterans;Graft Vs Host Disease | Drug: Pirfenidone 267 MG [Esbriet] | Stanford University | Genentech, Inc. | Completed | 18 Years | N/A | All | 30 | Phase 1 | United States |